Kornimate/medical-research-clean huggingface dataset:
a patient-centered communication tool (ur-goal) for older patients with acute myeloid leukemia, their caregivers, and their oncologists

Conditions: Acute Myeloid Leukemia

Summary: this is a pilot study to evaluate the usability and feasibility of a patient-centered communication tool (university of rochester-geriatric oncology assessment for acute myeloid leukemia or ur-goal) among 15 older patients with aml, their caregivers, and oncologists.

older adults with aml and their caregivers may benefit from help and support in understanding their treatment options. this pilot study seeks to evaluate the usability and feasibility of the ur-goal communication tool. the ur-goal tool will incorporate conjoint analysis to elicit patient preferences as well as assessments of fitness and prognostic awareness.

Eligibility criteria:
inclusion criteria for patients: * age ≥60 years (conventional definition of older age in aml) * newly diagnosed aml * considering treatment * able to provide informed consent * english-speaking inclusion criteria for caregivers: * selected by the patient when asked if there is a "family member, partner, friend or caregiver \[age 21 or older\] with whom you discuss or who can be helpful in health-related matters;" patients who cannot identify such a person ("caregiver") can be eligible for the study. a caregiver need not be someone who lives with the patient or provides direct hands-on care. a caregiver can be any person who provides support (in any way) to the patient. * able to provide informed consent * english-speaking inclusion criteria for oncologists: * a practicing oncologist * at least one of their patients are recruited to the study * english-speaking exclusion criteria: none
examination of fibrillation atria using magnetic resonance imaging and endocardial high-density mapping

Conditions: Atrial Fibrillation

Summary: cather ablation of non-paroxysmal atrial fibrillation is less effective compared to paroxysmal atrial fibrillation. therefore, new techniques have been developed, such as high-density mapping to determine areas of focal and rotational activities. the aim is to assess the clinical efficacy of ablation focal and rotational activities, and to assess the relation between the areas of focal and rotational activities with fibrosis of both atria assessed using magnetic resonance.

pateints with non-paroxysmal atrial fibrillation will be enrolled. before the procedure, cardiac magnetic resonance will be done to determine the extent and location of atrial fibrosis of both atria using dedicated software. the procedure itself will be done standardly, in alangosedation, from both femoral veins, using 10-pole catheter in the coronary sinus, intracardiac echocardiography, and two transseptal punctures by means of sl1 sheaths. octarey mapping catheter (biosense webster, usa) wil be inserted in the left atrium, and during ongoing atrial fibrillation, a maping of left atrium will be done to locate the areas of focal and rotational activities. afterthat, using smart touch ablation catheter (biosense webster, usa), pulmonary vein isolation will be done. when pvi is achieved, all areas of focal and rotational activities determined by high-density mapping will be performed. if sinus rhythm is achieved, the procedure is finished. if atrial fibrilaltion is organized to regular atrial, this regular tachacardia is mapped, ablated and the procedure is finished. if atrial fibrilaltion continues, mapping of the righ atrium using the same technique is done followed by catheter ablation of areas of focal and rotational activities. if atrial fibrillation is still present after all these ablation, electrical cardioversion will be done. patients will be discharged on following day. 5-day holter recording will be done in 3, 6, and 12 months during standard out-patient controls. the aim is to compare the findings of high-density mapping with findings on atrial mri (relation between fibrosis on mri and locations of rotational and focal activities). furher aim is to assess the efficaccy of this kidn of ablation, i.e. the sinus rhythm maintenance in 3,6, and 12 months.

Eligibility criteria:
inclusion criteria: * non-paroxysmal atrial fibrillation exclusion criteria: * creatinine \> 120 umol/l * claustrofobia * pregnancy * mechanical valve * significant valve disease * left ventricular dysfunction, ef less than 35%

Keywords: atrial fibrillation catheter ablation cardiac magnetic resonance high-density mapping
fecal microbiota transplantation for chronic functional constipation

Conditions: Chronic Functional Constipation; Intestinal Bacteria Flora Disturbance; Fecal Microbiota Transplantation

Summary: chronic functional constipation is a common digestive system disease, the incidence is increasing in recent years.it is reported that the occurrence and development of chronic functional constipation is closely related to imbalance of intestinal flora .moreover,types and quantity of intestinal flora may be related to intestinal motility. fecal microbiota transplantation as a new technology to rebuild intestinal flora has been used for several disease，but the clinical efficacy of chronic functional constipation by fecal microbiota transplantation needs to be further explored.

patients who meet the inclusion crit chronic functional constipation will be separated into two parts depending on acceptation or refuse of fecal microbiota transplantation.blood specimen from patients will be collected to analysis intestinal motility.

Eligibility criteria:
inclusion criteria: 1. subjects voluntarily participate in the trial and sign informed consent; 2. sex is not limited,ranging from 18 to 75 years old; 3. meet the diagnostic criteria for chronic functional constipation in patients; 4. patients has been ruled out organic diseases of the large intestine within 1 year by colonoscopy or barium enema examination, and stool routine and occult blood examination are normal within 1 month; 5. be able to communicate well with the researchers and follow the verification requirements. exclusion criteria: 1. does not meet the diagnostic criteria; 2. with severe primary heart, liver, lung, kidney, blood or affect the survival of serious diseases; 3. severe anemia and severe systemic infection; 4. suspected or indeed have alcohol, drug abuse history; 5. pregnancy or are preparing for pregnancy, and breastfeeding women; 6. those who are unwilling to accept the research measures or other reasons can not cooperate; 7. due to mental disorders can not give adequate informed consent; 8. participated in other clinical trials within 3 months before the start of the study; 9. researchers believe that participates are not suitable for other reasons in this clinical trial.

Keywords: chronic functional constipation intestinal bacteria flora disturbance fecal microbiota transplantation
abutment macro design and peri-implant tissues

Conditions: Edentulous

Summary: the aim of this study is to evaluate the effect of abutment macro-design on soft and hard tissue responses. this trial is designed as a randomized controlled clinical study in which two groups of fourteen partially edentulous patients will have as part of their treatment one implant placed in the maxillary premolar region.

implant placement and abutment design will be planned with a computer software for guided implant treatment (simplant). the surgical implant placement will be performed under manufacturer's protocol by placing the implant platform 1mm below the buccal aspect of the osteotomy (koutouzis et al 2013). virtually designed, permanent cad-cam fabricated abutments (atlantis, dentsply) with different configuration of the subcritical contour (emergence shape) will be connected to the implants and temporary crowns will be delivered. implants of the group 1 will have permanent abutments with a concave configuration of the subcritical contour (emergence shape). implants of the group 2 will have permanent abutments with a convex configuration of the subcritical contour (emergence shape). the patients will be restored with single crowns 3 months following implant installation. a randomization protocol will be produced from a computer-generated list for the distribution of subjects in the two treatment groups.

Eligibility criteria:
general inclusion criteria: * - age more than 21 years * absence of relevant medical conditions * availability for 12 month follow-up specific inclusion criteria: * one missing tooth in the maxillary premolar region * presence of two adjacent teeth at the implant site * absence of periodontal disease * healed osseous architecture enough to receive an implant with a diameter of at least 3.5 mm and a sufficient amount of bone for placing implants with a length of at least 9 mm general exclusion criteria: * - pregnancy at the screening visit. * smoking more than 10 cig/day specific exclusion criteria: * adjacent implants * presence of periapical radiolucency at the adjacent teeth * missing adjacent teeth

Keywords: dental implants
effectiveness of standard therapy of acne vulgaris

Conditions: Acne Vulgaris

Summary: this study was to evaluate the effectiveness of standard therapy for acne vulgaris (av) based on the clinical practice guidelines (cpg) in indonesia. the main questions it aims to answer were: 1. how is the clinical characteristics of patients with av in dr.cipto mangunkusumo hospital? 2. how is the effectiveness of standard therapy for av based on the cpg in indonesia in reducing the number of non-inflammatory, inflammatory, and total lesions and degree of acne severity? the clinical pratice guideline (cpg) used for analysis was cpg by dr.cipto mangunkusumo hospital 2017 in line with the date of patient visit. data of 724 patients with av in dr.cipto mangunkusumo hospital as recorded in the medical records were assessed for eligibility. data of 3-month-follow-up data of included subjects were collected and analyzed.

objective: to evaluate the effectiveness of standard therapy for acne vulgaris (av) based on the guidelines in indonesia design: an analytical retrospective observational study conducted from april 2023 through july 2023 using medical records of new acne patients between 2017 to 2019 from dr. cipto mangunkusumo national central general hospital. a total sample of patients with av who received standard therapy for acne vulgaris based on the guideline by dr.cipto mangunkusumo hospital in 2017 and not associated with systemic diseases or drugs were included. patients were classified into mild, moderate, or severe acne using lehmann grading system. primary outcomes were changes in the number of non-inflammatory, inflammatory, and total lesions, and the proportion of acne severity after 3 months of therapy.

Eligibility criteria:
inclusion criteria: * new patients with acne vulgaris in the year 2017 to 2019 * complete medical record data of 3-month follow-up, including data of: name, medical record number, sex, age, job, level of education, visit date, number of non-inflammatory, inflammatory, and total acne lesions, diagnosis of acne vulgaris based on lehmann grading system * acne treatment based on clinical practice guideline by dr.cipto mangunkusumo hospital 2017 exclusion criteria: * follow-up data less than 3 times in 3 months * incomplete medical record * av diagnosis without data on severity * history of systemic diseases associated with acne such as polycystic ovarian syndrome and cushing syndrome * history of allergy with one or more standard acne therapy based on the clinical practice guideline * received acne therapy not aligned with clinical practice guideline by dr.cipto mangunkusumo hospital

Keywords: acne vulgaris clinical practice guideline indonesia effectiveness therapy
ultralow dose pet imaging for psma expression

Conditions: Healthy Volunteer; Prostate CA

Summary: the goal of this clinical trial is to evaluate an investigational ultralow dose pet imaging technique for prostate cancer detection and monitoring. the main question it aims to answer is: can the investigators optimize the timing, scan duration, and image reconstruction to reduce the radiation dose 10-100 fold of the current clinical standard? participants will be injected with a radioactive tracer called 18f-dcfpyl and be imaged on a new type of high sensitivity pet scanner for up to 3 hours

this research study aims to evaluate an investigational ultralow dose pet imaging technique for prostate cancer detection and monitoring. "investigational" means that the procedure or drug being studied is not yet approved by the fda for the specific use being tested in this research. the pet imaging technique used in this study is considered investigational because it is being tested at an ultralow radiation dose that has not yet been approved for clinical use. the radiotracer, 18f-dcfpyl, is fda-approved for detecting prostate cancer at standard doses. 18f-dcfpyl attaches to a protein called psma, which is often found at higher levels on certain cancer cells, such as prostate cancer cells. in this study, investigators will use a very small amount of this tracer (less than 1/20th of the standard dose) along with advanced pet imaging technology to see if it is possible to create clear images while using much less radiation. this study aims to develop a safer imaging technique that could potentially be used more frequently for screening and monitoring prostate cancer. investigators will enroll individuals with and without prostate cancer to evaluate how ultralow dose pet imaging detects psma in different type of tissue. approximately 200 people will be enrolled in this study at the nuclear imaging institute.

Eligibility criteria:
inclusion criteria: 1. age ≥18 years. 2. ability to provide informed consent and comply with study procedures. 3. for female participants: * must not be pregnant or breastfeeding. * negative pregnancy test required for women of childbearing potential. exclusion criteria: 1. participants who have exceeded nrc regulation for annual radiation exposure from prior research-related scans, including this study (50 msv total). 2. more than four prior enrollments in this study. 3. participants with severe claustrophobia, chronic pain, or musculoskeletal conditions that prevent completion of the pet scan 4. medication \& prior treatment exclusions • concurrent psma-targeted therapy (e.g., lutetium-177). 5. pregnant or breastfeeding individuals (negative pregnancy test required) 6. inability to provide informed consent 7. any condition that, in the investigator's judgment, may compromise participant safety or study integrity.

Keywords: pet scan prostate cancer psma nuclear imaging
rollover study to provide continued access to tt-00420 (tinengotinib) for subjects with advanced solid tumors

Conditions: Advanced Solid Tumors; Cholangiocarcinoma

Summary: this study is an open-label, multicenter study for continued characterization of safety and tolerability of tt-00420 (tinengotinib) tablet monotherapy in adult patients with advanced solid tumors

this is a rollover study. only subjects who continue to receive clinical benefit from continuation of tinengotinib monotherapy and are tolerating tinengotinib at the time of enrollment are eligible to participate on this study. subjects on this rollover study may continue to receive tinengotinib at the dose that they were previously receiving on the transthera parent study and may continue for as long as the subject continues to benefit from treatment.

Eligibility criteria:
inclusion criteria: 1. subject is currently enrolled in a pre-defined transthera-sponsored parent study and is receiving tinengotinib as a single agent. 2. subject is currently deriving clinical benefit from the study treatment, as determined by the investigator. exclusion criteria: 1. subject has been permanently discontinued from tinengotinib in the parent protocol for any reason other than enrollment in the rollover study 2. subject does not meet the criteria specified in the parent protocol for continued treatment on study.
effect of subcision and suction on acne scars

Conditions: Acne Scars

Summary: the primary objective of this study is to determine whether the use of standard treatment in conjunction with suction will improve acne scars compared to a standard treatment alone.


Eligibility criteria:
inclusion criteria: * age 18 and over * have bilateral rolling acne scars * are in good health * subject has the willingness and ability to understand and provide informed consent for the use of their tissue and communicate with the investigator. exclusion criteria: * under 18 years of age * pregnancy or lactation * unable to understand the protocol or give informed consent * has mental illness * recent accutane use in the past 6 months * prone to hypertrophic and keloidal scarring
prediction of individual radiosensitivity during radiotherapy for breast cancer patients

Conditions: Radiation Tolerance; Breast Neoplasms

Summary: non-randomized clinical cohort study investigating if single nucleotide polymorphism (snp) or inflammatory markers can predict radiosensitivity in breast cancer patients receiving radiotherapy.

objectives 1. to explore if acute radiation response can be predicted in patients, by analyzing a single nucleotide polymorphism (snp rs1801516) sampled prior to radiotherapy. 2. if acute radiation response can be predicted in patients, by analyzing genetic and inflammatory markers in blood sampled prior to radiotherapy. 3. if late side effects from radiotherapy can be predicted in patients, by analyzing genetic and inflammatory markers in blood sampled before and after radiotherapy. 4. if there is a correlation between genetic and inflammatory markers in blood and patient reported outcome measures (prom) and quality of life (qol). 5. to train an algorithm to correlate the appearance of skin before radiotherapy and the extent of skin reaction to radiotherapy outline this study is a non-randomized clinical cohort study. adults with breast cancer will be invited to participate in the study. blood will be collected before start of treatment and after radiotherapy is completed. quality of life (qol) and symptoms will be assessed before and weekly during treatment, at the end of treatment and after one year. a total of 550 patients is expected to be recruited.

Eligibility criteria:
inclusion criteria: * patients receiving adjuvant radiotherapy for breast cancer 2,67 gy x 15 (or a radio biologically equivalent dose) * \> 18 years * being able to read and understand patient information in swedish * signed informed consent exclusion criteria: * ongoing infection * fever \>37,9 degrees celsius * unable to follow study protocol
role of st2 in acute pancreatitis

Conditions: Acute Pancreatitis

Summary: acute pancreatitis is characterized by an inflammatory storm which regulatory pathways are not well known. the il-1 cytokine family is activated early during acute pancreatitis and secretion of alarmins is speculated during pancreatic necrosis. il-33 is a member of the il-1 family, it can act as an alarmin and its receptor, st2, is known to sequester myd88 which might regulate the acute pancreatitis inflammatory storm. the aim of this study is to investigate st2 pathway in human acute pancreatitis and in murine experimental models of acute pancreatitis.


Eligibility criteria:
inclusion criteria: * time to take blood sample less than 24h after the onset of symptoms of ap * two of the following: typical pain, amylase and lipase concentrations more than 3x the upper normal limit, compatible modifications on imaging techniques exclusion criteria: * chronic pancreatitis
proteomic study of plasma exosomes in patients with diabetic retinopathy

Conditions: Diabetic Retinopathy

Summary: objective: explore the biomarkers related to proliferative diabetic retinopathy by analyzing the protein expression profile changes of plasma exosomes in patients with difference phases of diabetic retinopathy, and investigate potential molecular mechanisms and therapeutic targets. methods: enrich exosomes from plasma by column extraction method. nta, wb and tem were used to characterize the obtained exosomes, and exosome proteinomics was performed by chromatography⁃mass spectrometry. corhorts: the study was divided into four groups: a healthy control group, a diabetic without diabetic retinopathy group, a non-proliferative diabetic retinopathy group, and a proliferative diabetic retinopathy group, with 6 cases in each group.


Eligibility criteria:
inclusion criteria: * healthy volunteers without diabetes/ senile cataract patients without diabetes； * patients with diabetes who are diagnosed without dr, npdr, and pdr by mydriatic fundus photography (or ffa)； exclusion criteria: * patients with systemic diseases such as cancer, immune diseases, infectious diseases, and blood diseases； * patients with cerebral infarction, myocardial infarction and other cardiovascular and cerebrovascular diseases

Keywords: plasma exosome diabetic retinopathy
albumin administration in cirrhotic patients with bacterial infection and a systemic inflammatory response syndrome unrelated to spontaneous bacterial peritonitis

Conditions: Cirrhosis; Sepsis; Renal Failure

Summary: patients with cirrhosis present an increased susceptibility to bacterial infections. spontaneous bacterial peritonitis (sbp) is the most frequent infection and induces severe circulatory dysfunction associated with renal failure in about 30% of cases. renal failure is a reliable surrogate marker of in-hospital mortality in patients with sbp or with non-sbp infections. albumin, as an adjuvant to antibiotherapy reduces significantly the rate of renal failure, in-hospital mortality, and overall mortality (sort p, et al. nejm 1999). however, little is known regarding the effect of albumin administration in patients with non-sbp infections. two recent prospective studies demonstrated that non-sbp infections are associated with impairment of the effective circulating volume and precipitate renal failure whatever the presence of ascites. the aim of this randomized clinical trial is to evaluate the effects of albumin, associated with appropriate antibiotic therapy, on occurrence or deterioration of renal failure and survival in septic (sirs criteria required) cirrhotic patients with non-sbp infections and presenting with a child-pugh score \> 8.

* cirrhosis defined by clinical, laboratory or ultrasonographic findings * child-pugh \> 8 * sepsis defined by the presence of proved or suspected infection with two of the four sirs (systemic inflammatory response syndrome) criteria (wong f, et al. sepsis in cirrhosis: report on the 7th meeting of the international ascites club. gut 2005) * creatinine \< 160 µmol/l

Eligibility criteria:
inclusion criteria: * cirrhosis defined by clinical, laboratory or ultrasonographic findings * child-pugh \> 8 * sepsis defined by the presence of proved or suspected infection with two of the four sirs (systemic inflammatory response syndrome) criteria (wong f, et al. sepsis in cirrhosis: report on the 7th meeting of the international ascites club. gut 2005) * creatinine \< 160 µmol/l * written informed consent * absence of the exclusion criteria exclusion criteria: * spontaneous bacterial peritonitis * difficult to treat infections such as : endocarditis, septic arthritis, osteomyelitis * heart insufficiency (yha iii-iv) * digestive bleeding during the week preceding the study * septic shock * hepatocellular carcinoma : stage d * use of antibiotics during the week preceding the study, except noroxin used for long-term antibioprophylaxy * diseases which can influence the short term survival
semen analysis after proton therapy for prostate cancer

Conditions: Prostate Cancer

Summary: the purpose of this study is to evaluate semen for changes following treatment with proton radiation therapy.


Eligibility criteria:
inclusion criteria: - diagnosis of low to intermediate risk prostate cancer and elected to have proton radiation therapy at university of florida proton therapy institute (ufpti). exclusion criteria: * current use of flomax, hytrin, cardura, uroxatral, or rapaflo. * history of vasectomy. * current use of lupron, zoladex, trelstar, casodex, eulexin. * current use of avodart or proscar.

Keywords: semen analysis, prostate cancer, proton radiation